ImmuCell Corporation (ICCC) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -3.8%, revenue growth 11.5% YoY, P/E 114.2. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $27.64M |
| Revenue (TTM) | $0.0B |
| Net Margin | -3.8% |
| Operating Margin (TTM) | 12.6% |
| Net Debt / EBITDA | -0.1 |
| Revenue Growth (YoY) | 11.5% |
| EPS Growth (YoY) | 233.3% |
| FCF Growth (YoY) | 58.0% |
| P/E Ratio | 114.2 |
| EV / EBITDA | 13.4 |
| Price / Book | 2.86 |
| Price / Sales | 2.93 |
| FCF Yield | 1.4% |
| Altman Z-Score | 4.13 (safe) |
| Piotroski F-Score | 7/9 |
| Piotroski checks passed | 7 of 9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.6 |
ICCC overview · ICCC earnings · ICCC KPIs · ICCC documents · ICCC ownership · ICCC peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.